| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/03/2002 | WO2002000252A2 Non-human animal models of tolerance to hepatitis c virus immunogenes |
| 01/03/2002 | WO2002000251A1 Vaccine against foot-and-mouth disease |
| 01/03/2002 | WO2002000250A2 Hiv-1 vaccines and screening methods therefor |
| 01/03/2002 | WO2002000249A2 Multivalent vaccine composition |
| 01/03/2002 | WO2002000245A1 Neurotoxic oligomers |
| 01/03/2002 | WO2002000242A2 Human papilloma virus treatment |
| 01/03/2002 | WO2002000232A2 Methods and compositions for developing spore display systems for medicinal and industrial applications |
| 01/03/2002 | WO2002000174A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001068134A3 Therapies that improve graft survival, using antibodies against a b7 antigen |
| 01/03/2002 | WO2001058941A8 Cytokine activity regulator molecules from tick salivary glands |
| 01/03/2002 | WO2001058472A3 Botulinum toxin pharmaceutical compositions |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001051083A3 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 01/03/2002 | WO2001049713A3 Stabilizing peptides, polypeptides and antibodies which include them |
| 01/03/2002 | WO2001046696A3 Methods and compositions for detecting hepatitis e virus |
| 01/03/2002 | WO2001046383A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 01/03/2002 | WO2001042297A3 Clasp-3 transmembrane protein |
| 01/03/2002 | WO2001041800A3 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 01/03/2002 | WO2001039799A3 Passive desensitization |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2001032843A3 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | WO2000059935A9 Anti-apoptotic fusion polypeptide |
| 01/03/2002 | US20020002273 Rapamycin assay |
| 01/03/2002 | US20020002272 Eliciting HCV-specific antibodies |
| 01/03/2002 | US20020002271 Separating immunoglobulin from mixture; load sample onto chromatographic apparatus, elute immunoglobulin |
| 01/03/2002 | US20020002162 Synergistic methods and compositions for treating cancer |
| 01/03/2002 | US20020002143 AIDS virus vaccines using sendai virus vector |
| 01/03/2002 | US20020001841 Continuous t-cell lines |
| 01/03/2002 | US20020001805 Nucleotide sequence for use in the detection, diagnosis and treatment of tumor of urogenital system |
| 01/03/2002 | US20020001798 Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| 01/03/2002 | US20020001597 Eliciting in vertebrate a protective immune response against bacterium of the genus Chlamydia; carrier group coupled to oligosaccharide |
| 01/03/2002 | US20020001596 Prophylactic and therapeutic method |
| 01/03/2002 | US20020001595 Sampling antigen-containing blood and/or tissue; obtaining liquid/homogenate; adding crosslinking agent; heating to solidification; mixing with pyrogen-free salt solution; for treatment of AIDS, HIV |
| 01/03/2002 | US20020001594 Pharmacological compound having pressure reductive activity |
| 01/03/2002 | US20020001593 Produced by inserting a foreign nucleotide sequence (from chlolera, enterotoxin, pilin, HIV protective epitope, flagellin, or cytokine) encoding an immunogenic peptide; plasmids; vaccines |
| 01/03/2002 | US20020001592 Use of Botulinum toxins for treating various disorders and conditions and associated pain |
| 01/03/2002 | US20020001591 Compositions for the delivery of antigens |
| 01/03/2002 | US20020001589 Complex of lipooligosaccharide and immunology carriers |
| 01/03/2002 | US20020001586 Inhibiting proliferation of neural cells via contacting with antibody, antisense nucleotide, and/or polynucleotide that disrupts activity of granulin molecule |
| 01/03/2002 | US20020001585 Administering a blocking agent of tumor necrosis factors or receptors; treatment of Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue viral disease |
| 01/03/2002 | US20020001576 Medicaments containing allogenic activated-CD4+ cells as the main ingradient, which are attributable to an organ or bone marrow implant donor, have extreemly beneficial effect for preventing tumor and various infections |
| 01/03/2002 | CA2783274A1 Vaccine composition |
| 01/03/2002 | CA2648051A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2417699A1 Helicobacter pylori heptosyl transferase polypeptides |
| 01/03/2002 | CA2417692A1 Helicobacter dd-heptosyltransferase |
| 01/03/2002 | CA2415238A1 Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
| 01/03/2002 | CA2414308A1 Transport peptides derived from erns protein, cytotoxic rnase of ribosome-inactivating protein or a rsv g-protein and analogues thereof |
| 01/03/2002 | CA2414089A1 Improvements in and relating to chromophores |
| 01/03/2002 | CA2413800A1 Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof |
| 01/03/2002 | CA2413786A1 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes |
| 01/03/2002 | CA2413543A1 Human papilloma virus treatment |
| 01/03/2002 | CA2413354A1 Neurotoxic a.beta. oligomers in alzheimer's disease |
| 01/03/2002 | CA2412621A1 Rescue of canine distemper virus from cdna |
| 01/03/2002 | CA2412612A1 Eg-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | CA2412503A1 A method of treating and preventing infectious diseases |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412211A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2412089A1 Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
| 01/03/2002 | CA2412084A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | CA2411167A1 Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use |
| 01/02/2002 | EP1167530A2 PVX capsid-antigen fusion protein, chimaeric viral particles displaying it on the capsid, plants infected with said particles, their uses and compositions comprising them |
| 01/02/2002 | EP1167389A1 Antibodies against the protein SEMP1, methods for their production and uses thereof |
| 01/02/2002 | EP1167386A1 Canine and feline melanocortin-4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 01/02/2002 | EP1167384A1 HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1166797A1 Method of controlling the qualities of attenuated pox vaccine |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165818A2 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/02/2002 | EP1165817A1 Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
| 01/02/2002 | EP1165805A1 Dsp-2 dual-specificity map kinase phosphatase |
| 01/02/2002 | EP1165798A2 Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
| 01/02/2002 | EP1165796A2 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| 01/02/2002 | EP1165795A2 Streptococcus pneumoniae antigens |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165778A2 Casb618 polynucleotides and polypeptides and their use |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165774A2 Casb619 involved in colon cancers |
| 01/02/2002 | EP1165773A1 Advanced antigen presentation platform |
| 01/02/2002 | EP1165756A2 Adaptation of virus to vertebrate cells |
| 01/02/2002 | EP1165617A2 Anti-plasmodium compositions and methods of use |
| 01/02/2002 | EP1165616A1 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 01/02/2002 | EP1165615A2 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 01/02/2002 | EP1165614A1 Antibodies against phosphomannan that are protective against candidiasis |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165600A1 Proteins modified by xanthurenic acid |
| 01/02/2002 | EP1165598A1 Hookworm platelet inhibitor |
| 01/02/2002 | EP1165586A1 TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS |
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165144A2 Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
| 01/02/2002 | EP1165142A2 Lipid-based artificial particles inducing cell-mediated immunity |
| 01/02/2002 | EP1165140A2 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/02/2002 | EP1165134A1 Use of anti-ferritin monoclonal antibodies in the treatment of some cancers |
| 01/02/2002 | EP1165132A2 Dry formulation for transcutaneous immunization |